Effect of Ramipril therapy on walking ability and quality of life in patients with intermittent claudication
Ahimastos, Anna, Walker, Phillip, Askew, Christopher, Leicht, Anthony, Pappas, Elise, Blombery, Peter, Reid, Christopher, Golledge, Jonathan, and Kingwell, Bronwyn (2012) Effect of Ramipril therapy on walking ability and quality of life in patients with intermittent claudication. Journal of Hypertension, 30 (e-Supplement 1). e114-e114.
|PDF - Requires a PDF viewer such as GSview, Xpdf or Adobe Acrobat Reader|
View at Publisher Website: http://www.jhypertension.com
Background: One third of patients with peripheral artery disease (PAD) experience intermittent claudication, with the major consequence being loss of quality of life. This study was conducted to determine the efficacy of ramipril in improving walking ability and quality of life in patients with PAD.
Design and Methods: 200 PAD patients (66 +/- 6 years (mean +/- SD) were randomised to receive ramipril, 10 mg once daily (n = 99) or placebo (n = 101) for 24 weeks in a double blind study. Pain free walking time (PFWT) and maximum walking time (MWT) were determined using a standard exercise treadmill test. The standard Walking Impairment Questionnaire (WIQ) and Short Form-36 (SF-36) questionnaire were administered to quantify walking ability and quality of life respectively.
Results: Ramipril increased PFWT by 92% (Placebo 8.9 +/- 2 secs; Ramipril 87.2 +/- 65.8; p < 0.0001) and MWT by 139% (Placebo 14.4 +/- 32.9 secs; Ramipril 192.7 +/- 125.9; p < 0.0001). The treatment group reported significantly higher scores on the distance (Placebo -3.4 +/- 7.0; Ramipril 12.4 +/- 9.5; p < 0.0001), speed (Placebo -3.2 +/- 4.5; Ramipril 11.1 +/- 7.8; p < 0.0001) and stair climbing (Placebo -7.1 +/- 10.5; Ramipril 23.8 +/- 18.7; p < 0.0001) subscales of the WIQ. The treatment group also reported higher scores on the physical functioning subscale of the SF-36 (Placebo -0.1 +/- 0.9, Ramipril 2.1 +/- 2.8; p < 0.0001).
Conclusions: This is thefirst adequately powered randomized trial demonstrating that ACE inhibition improves walking ability and quality of life in patients with PAD; an improvement substantially beyond that reported with conventional medical therapies.
© 2012 Lippincott Williams & Wilkins, Inc.
|Item Type:||Article (Abstract)|
This supplement contains the Abstracts of the 24th Meeting of the International Society of Hypertension, Sydney, Australia, 30 September - 4 October 2012.
|FoR Codes:||11 MEDICAL AND HEALTH SCIENCES > 1102 Cardiovascular Medicine and Haematology > 110201 Cardiology (incl Cardiovascular Diseases) @ 100%|
|SEO Codes:||92 HEALTH > 9201 Clinical Health (Organs, Diseases and Abnormal Conditions) > 920103 Cardiovascular System and Diseases @ 60%|
92 HEALTH > 9205 Specific Population Health (excl. Indigenous Health) > 920502 Health Related to Ageing @ 40%
|Deposited On:||30 Nov 2012 11:32|
|Last Modified:||30 Nov 2012 11:32|
Last 12 Months: 46
Repository Staff Only: item control page